CHINESE JOURNAL OF CHEMICAL ENGINEERING
·
2019
·
IF 1.911
Zheng Zhang,Yuanhui Ji,Wei Chen
In this work, hollow manganese dioxide/gold nanoparticle (MnO 2 /GNPs) hybrid drug nanocarriers were prepared by coupling the gold nanoparticles (GNPs) with hollow structure manganese dioxide (MnO 2 ). Among them, GNPs have been used as near-infrared (NIR)-responsive element for photothermal effect under NIR laser irradiation. The glutathione (GSH)-responsive and pH-responsive performances of drug release were derived from hollow MnO 2 . Particularly, Doxorubicin hydrochloride (DOX) can be loaded into hollow MnO 2 /GNPs with the drug loading efficiency up to 82.0%. Moreover, the photothermal effect and GSH-/pH-responsive properties of hollow MnO 2 /GNPs were investigated. The hollow MnO 2 /GNPs possessed satisfactory drug release efficiency ( ca. 87.4% of loaded drug released in 12 h) and have high photothermal conversion efficiency, multiresponsive properties, and degradability. Finally, the kinetics of drug release was discussed in detail. Thus, our finding highlights that the multiresponsive nanocarriers are of great potential in the field of drug controlled release.
研究领域:
生物医学工程
·
纳米医学
·
药剂学
✓ 已验证
产品关联
DOI
高影响因子
FUEL
·
2024
·
IF 6.7
Junhong Chen,Zhiwei Huang,Xinlong Liao,Shuangning Gan,Mingshuo Tian,Jiangwei Ni,Qiqi Zhou,Wen Chen,Juanjuan Gong,Jing Dong,Jia Chen,Huazhen Shen,Xiaomin Wu,Huawang Zhao,Guohua Jing
Tackling the urgent need for efficient catalytic abatement of harmful volatile organic compounds (VOCs), this study presents the controlled synthesis of hollow MnO 2 microcuboids with hierarchical structures for enhanced benzene oxidation catalysis. The hollow MnO 2 catalysts, obtained via a redox reaction between MnCO 3 precursors and KMnO 4 followed by selective acid etching, exhibit significantly higher surface area, oxygen defects, and Mn 3+ concentration compared to solid MnO 2 . Comprehensive characterization techniques reveal the structure–activity relationships governing the superior catalytic performance, which rivals that of a 1 % Pt/Al 2 O 3 reference catalyst. The unique hollow morphology, comprising thin shell walls built from interconnected nanorods, substantially enhances active site accessibility and lowers the activation energy barrier. A key feature of the hollow structure is its ability to concentrate reactants within the confined internal void through capillary action, a phenomenon that enriches reactant concentrations and further promotes catalytic activity. In-situ DRIFTS analyses provide mechanistic insights into surface species transformations during benzene oxidation. Notably, the hollow MnO 2 catalyst demonstrates impressive long-term stability and high activity in the presence of water vapor, highlighting its potential for practical industrial VOC abatement applications.
研究领域:
材料科学
·
环境科学
✓ 已验证
产品关联
DOI
高影响因子
Cancer Nanotechnology
·
2023
·Vol. 14
·期 1
·1-19
·
IF 5.7
Wu Yueyao,Wang Runtian,Shen Peiliang,Zhou Weijia,Chen Chao,Yang Kaiyong,Yang Jingjing,Song Yujun,Han Xin,Guan Xiaoxiang
Cancer treatment by inducing tumor cell immunogenic cell death (ICD) is critical for tumor therapy. However, ICD activation by single pathway is often limited in practical application due to its low efficiency. In addition, the low pH and anoxic microenvironments in solid tumors greatly limit the effective activation of ICD. Herein, hollow manganese dioxide (H-MnO2) nanomaterials were selected to load both Mitoxantrone (MTZ) and Chlorin e6 (Ce6) due to its hollow structure and ability to release drugs in the acidic environments. Thus, the synergy of photodynamic therapy (PDT), photothermal therapy (PTT) and chemotherapy can induce the process of immunogenic cell death, stimulate the maturation of dendritic cells (DCs), and activate the immune response to kill tumor cells dramatically. Efficient immunotherapeutic effects were obtained when MnO2-C/M-HA was given intravenously to 4T1 tumor-bearing BALB/c mice with 660 nm near-infrared laser irradiation. This study overcame the limitations of monotherapy and provided a multifunctional platform for tumor immunotherapy.
研究领域:
癌症治疗
·
纳米技术
·
免疫学
·
药物递送系统
✓ 已验证
产品关联
DOI
高影响因子
ACS Applied Nano Materials
·
2022
·
IF 6.14
Weicai Wang,Xiaozu Chen,Junwei Li,Qiu Jin,Hyung Jong Jin,Xuemei Li
Nanotechnology provides more developments and challenges for cancer immunotherapy. Nanomaterial-mediated synergistic therapy, immunosuppressive adjustment of the tumor microenvironment (TME), and nanovaccine construction can promote cancer immunotherapy. Here, based on the biodegradable hollow manganese dioxide (H-MnO2) tumor-targeted drug delivery platform, we have developed a TME-responsive nanovaccine for synergistic cancer therapy. The nanoplatform significantly enhanced photodynamic therapy (PDT)-mediated immune response by improving the hypoxic tumor microenvironment and on-demand drug release. At the same time, it was supplemented with gene therapy and chemotherapy to achieve significant in vivo combined therapy benefits. Taking full advantage of the high reactivity to the hydrogen peroxide and weak acidity of the TME, H-MnO2 loaded with chemotherapy drug doxorubicin (DOX) and photosensitizer chlorin e6 (Ce6) not only provided the required oxygen for photodynamic therapy but also reduced the side effects of chemotherapy drugs on normal tissues. Moreover, the coating of nucleic acid on H-MnO2 solved the problem of biocompatibility of nanoparticles and ensured that they could be swallowed by cancer cells. The results revealed that through the controlled release of targeted drugs and combined therapy, the synergistic nanovaccine significantly inhibited tumor growth in mice, which is expected to achieve the treatment of primary tumors.
研究领域:
纳米技术
·
癌症免疫治疗
·
药物递送系统
·
光动力疗法
·
基因治疗
·
化疗
·
生物相容性
✓ 已验证
DOI
高影响因子
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
·
2024
·
IF 7.7
Yun Liu,Ziying Zhang,Yu Xia,Mengnan Ran,Qing Wang,Quanxin Wu,Wenhua Yu,Cao Li,Shiying Li,Ning Guo
In addition to tumor cells, M2-like tumor-associated macrophages (TAMs) also promote tumor progression. Accordingly, the strategy of targeted depletion or repolarization of M2-like TAMs becomes attractive. Here, we report a dual-targeting nanoagent SAMMH to tumor cells and M2-like TAMs for combinatorial tumor treatment. After co-loading the sonosensitizer spafloxacin (SPX) and oxidative phosphorylation inhibitor atavaquone (ATO) into hollow MnO 2 , the addition of Fe 3+ and tannic acid-immobilized hyaluronic acid (HA) caused the formation of SAMMH through generating metal-polyphenol networks (MPNs) coatings outside. In vitro endocytosis assays demonstrated the efficient internalization of SAMMH by both tumor cells and M2-like TAMs through the specific CD44-HA interactions. The GSH-sensitive degradation of SAMMH results in the continuous release of SPX and ATO. Meanwhile, SAMMH could catalyze the endogenous H 2 O 2 to extra O 2 , thus improving the therapeutic effect via the combination of Mn 2+ -induced CDT and O 2 -generation/O 2 -economy dual-enhanced sonodynamic therapy (SDT). Interestingly, SAMMH had a good targeted M2-like TAMs depleting capacity and could promote M2-to-M1 TAMs transformation by CDT-enhanced SDT, leading to a combinational anti-tumor effect. This dual-targeting nanoagent is a promising candidate to achieve CDT-enhanced SDT against both tumor cells and M2-like TAMs, thus providing new insights for the development of highly effective antitumor therapeutics.
研究领域:
癌症治疗
·
纳米医学
·
药学
·
生物医学工程
✓ 已验证
产品关联
DOI
PubMed
高影响因子
危险品化学品经营许可证（带存储）